Novavax could offer unvaccinated Americans a new option, if regulators agree
CBSN
Following a long-awaited submission of data to the Food and Drug Administration last month, Novavax announced Monday that it had formally filed a request for emergency use authorization of its protein-based COVID-19 vaccine in the United States.
If greenlighted by the FDA, Novavax's shots could be the first COVID-19 doses available in the U.S. based on a kind of "protein subunit" technology that has been used for decades in other routine vaccinations. Officials say having this option could help persuade some remaining vaccine holdouts to get the shots, as well as boost the Biden administration's international vaccine donation goals.
"We believe our vaccine offers a differentiated option built on a well-understood protein-based vaccine platform that can be an alternative to the portfolio of available vaccines to help fight the COVID-19 pandemic," Novavax's president and CEO Stanley Erck said in a statement announcing the submission.
